Smith & Nephew SNATS, Inc. $SNN Shares Acquired by River Road Asset Management LLC

River Road Asset Management LLC lifted its position in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 13.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,169,644 shares of the medical equipment provider’s stock after acquiring an additional 384,926 shares during the period. Smith & Nephew SNATS accounts for 1.1% of River Road Asset Management LLC’s holdings, making the stock its 29th largest position. River Road Asset Management LLC owned about 0.75% of Smith & Nephew SNATS worth $103,996,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in SNN. Garner Asset Management Corp acquired a new position in Smith & Nephew SNATS in the 4th quarter valued at $27,000. Arax Advisory Partners boosted its stake in Smith & Nephew SNATS by 142.6% during the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in Smith & Nephew SNATS during the 4th quarter worth $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS during the third quarter worth $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of Smith & Nephew SNATS during the fourth quarter worth $43,000. 25.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SNN shares. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Sanford C. Bernstein set a $31.85 price objective on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Kepler Capital Markets downgraded shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, Weiss Ratings lowered shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Trading Up 0.1%

Shares of SNN stock opened at $30.11 on Friday. The company’s 50-day moving average price is $31.15 and its 200-day moving average price is $32.75. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.57 and a quick ratio of 1.25. Smith & Nephew SNATS, Inc. has a twelve month low of $28.78 and a twelve month high of $38.79.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The firm had revenue of $1.60 billion for the quarter. As a group, equities analysts expect that Smith & Nephew SNATS, Inc. will post 2.22 earnings per share for the current year.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.